Sort   by:  
 Page size 
UnknownToll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma.
Not available
S-EPMC5955093 | biostudies-literature
UnknownGenome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
Not available
S-EPMC4879713 | biostudies-literature
UnknownEvent-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Not available
S-EPMC3965261 | biostudies-literature
UnknownEZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Not available
S-EPMC9892962 | biostudies-literature
UnknownRationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
Not available
S-EPMC4938339 | biostudies-literature
UnknownThe expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.
Not available
S-EPMC2675107 | biostudies-literature
UnknownA phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Not available
S-EPMC4731845 | biostudies-literature
UnknownPembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Not available
S-EPMC6881098 | biostudies-literature
UnknownUnclassifiable Isolated Monoclonal Lymphocytosis: Comprehensive Description of a Retrospective Cohort.
Not available
S-EPMC6826630 | biostudies-literature
UnknownCAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Not available
S-EPMC8893508 | biostudies-literature
Sort   by:  
 Page size